Poziotinib, an oral irreversible pan‐HER TKI, demonstrated a promising ORR of 35.1% in HER2‐mutated NSCLC in a phase II trial, ZENTITH20‐2.377. Here, ERBB2 is linked to non-small cell lung carcinoma.